Univariate and multivariate analyses of factors associated with OS of overall patients with ENKTL
| Variable . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age > 60 y | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 0.70 | 0.32-1.57 | .392 | — | — | — |
| B symptoms | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.29 | 0.55-2.98 | .558 | — | — | — |
| Stage | ||||||
| I | 1 | — | — | 1 | — | — |
| II, III, or IV | 3.07 | 1.30-7.26 | .011 | 3.07 | 1.09-8.67 | .034 |
| Serum LDH > ULN | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.00 | 0.79-5.11 | .146 | — | — | — |
| Nasal lesion | ||||||
| Present | 1 | — | — | — | — | — |
| Absent | 0.93 | 0.40-2.16 | .863 | — | — | — |
| Regional LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.24 | 0.54-2.83 | .605 | — | — | — |
| Distant LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.04 | 0.31-3.50 | .952 | — | — | — |
| Treatment | ||||||
| AC–free CTX and/or RT | 0.29 | 0.08-1.01 | .051 | 0.22 | 0.06-0.88 | .032 |
| Other CTX | 0.47 | 0.10-2.14 | .331 | 0.45 | 0.07-2.97 | .404 |
| No (including BSC) | 1 | — | — | 1 | — | — |
| STAT3 mutation | ||||||
| Negative | 1 | — | — | — | — | — |
| Positive | 1.25 | 0.51-3.06 | .630 | — | — | — |
| BCOR mutation | ||||||
| Negative | 1 | — | — | 1 | — | — |
| Positive | 6.66 | 2.25-19.69 | <.001 | 5.11 | 0.56-46.97 | .149 |
| TP53 mutation | ||||||
| Negative | 1 | — | — | 1 | — | — |
| Positive | 4.06 | 1.55-10.59 | .004 | 0.89 | 0.13-6.17 | .902 |
| pSTAT3 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.04 | 0.81-5.11 | .129 | — | — | — |
| CD30 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.67 | 0.76-3.67 | .200 | — | — | — |
| MYC ≥ 40% | ||||||
| No | 1 | — | — | 1 | — | — |
| Yes | 2.62 | 1.13-6.09 | .025 | 3.92 | 1.28-12.02 | .017 |
| Variable . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Age > 60 y | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 0.70 | 0.32-1.57 | .392 | — | — | — |
| B symptoms | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.29 | 0.55-2.98 | .558 | — | — | — |
| Stage | ||||||
| I | 1 | — | — | 1 | — | — |
| II, III, or IV | 3.07 | 1.30-7.26 | .011 | 3.07 | 1.09-8.67 | .034 |
| Serum LDH > ULN | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.00 | 0.79-5.11 | .146 | — | — | — |
| Nasal lesion | ||||||
| Present | 1 | — | — | — | — | — |
| Absent | 0.93 | 0.40-2.16 | .863 | — | — | — |
| Regional LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.24 | 0.54-2.83 | .605 | — | — | — |
| Distant LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.04 | 0.31-3.50 | .952 | — | — | — |
| Treatment | ||||||
| AC–free CTX and/or RT | 0.29 | 0.08-1.01 | .051 | 0.22 | 0.06-0.88 | .032 |
| Other CTX | 0.47 | 0.10-2.14 | .331 | 0.45 | 0.07-2.97 | .404 |
| No (including BSC) | 1 | — | — | 1 | — | — |
| STAT3 mutation | ||||||
| Negative | 1 | — | — | — | — | — |
| Positive | 1.25 | 0.51-3.06 | .630 | — | — | — |
| BCOR mutation | ||||||
| Negative | 1 | — | — | 1 | — | — |
| Positive | 6.66 | 2.25-19.69 | <.001 | 5.11 | 0.56-46.97 | .149 |
| TP53 mutation | ||||||
| Negative | 1 | — | — | 1 | — | — |
| Positive | 4.06 | 1.55-10.59 | .004 | 0.89 | 0.13-6.17 | .902 |
| pSTAT3 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.04 | 0.81-5.11 | .129 | — | — | — |
| CD30 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.67 | 0.76-3.67 | .200 | — | — | — |
| MYC ≥ 40% | ||||||
| No | 1 | — | — | 1 | — | — |
| Yes | 2.62 | 1.13-6.09 | .025 | 3.92 | 1.28-12.02 | .017 |
BSC, best supportive care; LN, lymph node; RT, radiotherapy; UNL, upper normal limit.